George Prendergast

Dr. Prendergast is the President and CEO of the Lankenau Institute for Medical Research (LIMR) and led the discovery and development of indoleamine 2,3 dioxygenase-1 (IDO1) inhibitors as anti-cancer agents. He was Editor-in-Chief of Cancer Research, a peer-reviewed and highly cited scientific journal published by the American Association for Cancer Research (AACR) from 2010-2017. He is a graduate of the University of Pennsylvania, where as a Benjamin Franklin Scholar he earned a bachelor’s degree magna cum laude with distinction in Biochemistry. He received his master’s degree in Molecular Biophysics and Biochemistry from Yale University and his doctorate in Molecular Biology from Princeton University. After obtaining advanced training as an American Cancer Society postdoctoral fellow at the Howard Hughes Medical Institute at NYU Medical Center, he joined the Department of Cancer Research at Merck Research Laboratories. In 1993, Dr. Prendergast was appointed assistant professor and later associate professor at The Wistar Institute in Philadelphia, where he was designated a Pew Scholar in the Biomedical Sciences. Subsequently, he became the senior director of the Cancer Research Group at the DuPont Pharmaceutical Company. In 2002, he moved his research efforts at Wistar and DuPont to LIMR. He brings a wealth of experience in basic and clinical oncology research, preclinical drug discovery and development.